Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 8;41:54. doi: 10.1186/s13046-021-02221-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

PMC Copyright notice

Fig. 1 — High co-expression of S100A7 and cPLA2 (PLA2G4A) is associated with poor clinical prognosis in breast cancer. Representative immunohistochemistry (IHC) images of (A). S100A7 and (D). cPLA2 proteins in malignant breast tumor samples (n = 36) and normal tissues (n = 46) [source: US Biomax]. Percent high-positive cells were quantified (right). Non-parametric test (Mann-Whitney U test) was applied. Relative mRNA expression (log2 fold change) of S100A7 and cPLA2 (PLA2G4A) were analyzed in low (n = 82) and high grades (n = 450) of breast tumor tissues using (B & E). GENT2 database (http://gent2.appex.kr/gent2/) and (C & F). also in low (n = 39) and high (n = 183) grades of breast cancer samples using Caldas & Chin datasets (n = 222). t test was used to calculate the p values (G). Correlation analysis between S100A7 and cPLA2 protein levels (% high positive) in a tumor tissue microarray (TMAs) of malignant breast cancer patients (n = 74) (H). Heatmap showing the correlation of S100A7 and cPLA2 in distinct signal transduction pathways (correlation coefficient = 0.93; NCBI GEO dataset: GSE39965) and expression in breast tumor tissues of pre-and post-chemotherapy (correlation coefficient = 0.59; NCBI GEO dataset: GSE18728). The pre and post chemotherapy analysis of baseline gene expression comprised baseline samples from 28 breast cancer patients which include17 non-responders and 11 responders. Analyses of gene expression changes involved paired baseline and post-cycle one specimens from 14 patients; of these 8 patients were non-responders and 6 patients were responders. (source: SEEK database). KM-plotter survival analysis (gene chip) of (I). S100A7 (PSOR1) alone, (J). cPLA2 (PLA2G4A) alone and (K). Combined S100A7 and cPLA2 (analysis include only patients with high median expression of genes) mRNAs expression with overall survival (OS) probability of immunomodulatory (IM) subtype of breast cancer patients. ns: non-significant, *P < 0.05, ** P < 0.01, *** P < 0.001, **** P < 0.0001. scale bar: 300 μm